Aural Analytics, Inc., a leader in clinical-grade speech analytics, announced today a partnership with Koneksa, a leader in digital biomarker development, to further strengthen its platform and research capabilities using Aural Analytics’ technology, Speech Vitals.
Speech is a leading objective data stream that facilitates a better understanding of disease progression and can be applied to support advanced methods of care delivery at home and in the clinic. The current state of neurology relies heavily on functional rating scales and self-reporting from patients. Aural Analytics’ Speech Vitals would provide additional value on top of what those existing tools provide so that clinicians can make better decisions.
“Partnerships with leading digital research providers such as Koneksa strengthen our reach across the research ecosystem and advance our mission to develop best-in-class, clinical-grade speech analytics”, “Koneksa and Aural Analytics share a vision in which speech analytics are an essential element of best-in-class digital biomarkers, which in time will further the fields of research and clinical care across neurodegenerative conditions.”
Judy Smythe, CEO of Aural Analytics
“We’re excited to work with Aural Analytics to integrate speech collection in our clinical trials”, “Through this partnership, our teams will develop best-in-class digital biomarkers to pioneer a better care experience, with a particular focus in neurodegenerative conditions.”
Chris Benko, Chief Executive Officer and Co-Founder, Koneksa
Aural Analytics and Koneksa’s leading research-grade platforms are optimized to support clinical trials at scale across development and commercial pharma pipelines. The goal of this integration is to make it easy to add speech measures to Koneksa studies and digital biomarker development programs.
